NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ENGN

enGene Holdings Inc

Jul 03 • 03:56PM ET

3.80

Dollar change +0.06
Percentage change 1.60	%

Healthcare • Biotechnology • Canada • NASD

Peers: CRSP NTLA EDIT QURE SRPT SGMO VYGR ADVM ADAP BNTC

| Held by: AVSC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.65	Insider Own	57.16%	Shs Outstand	51.07M	Perf Week	5.85%
Market Cap	194.20M	Forward P/E	-	EPS next Y	-2.25	Insider Trans	0.00%	Shs Float	21.89M	Perf Month	-9.52%
Enterprise Value	2.10M	PEG	-	EPS next Q	-0.50	Inst Own	40.70%	Short Float	0.23%	Perf Quarter	-14.41%
Income	-79.88M	P/S	-	EPS this Y	-37.62%	Inst Trans	-27.36%	Short Ratio	0.62	Perf Half Y	-43.70%
Sales	0.00M	P/B	0.85	EPS next Y	-11.86%	ROA	-29.57%	Short Interest	0.05M	Perf YTD	-42.86%
Book/sh	4.45	P/C	0.89	EPS next 5Y	-9.68%	ROE	-33.97%	52W High	11.00 -65.45%	Perf Year	-58.01%
Cash/sh	4.26	P/FCF	-	EPS past 3/5Y	-367.33% -	ROIC	-32.12%	52W Low	2.65 43.40%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.83% 11.31%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	69.23%	Oper. Margin	-	ATR (14)	0.34	Perf 10Y	-
Dividend Ex-Date	Aug 03, 2015	Quick Ratio	12.66	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	57.73	Recom	1.10
Dividend Gr. 3/5Y	- -	Current Ratio	12.66	EPS Q/Q	-33.19%	SMA20	11.63%	Beta	-0.41	Target Price	23.00
Payout	-	Debt/Eq	0.11	Sales Q/Q	-	SMA50	4.83%	Rel Volume	0.55	Prev Close	3.74
Employees	57	LT Debt/Eq	0.09	Earnings	Jun 12 BMO	SMA200	-35.91%	Avg Volume	82.04K	Price	3.80
IPO	Feb 01, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	-2.55% -	Trades		Volume	45,357	Change	1.60%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-18-25	Initiated	Piper Sandler	Overweight	$26
Feb-14-25	Downgrade	UBS	Buy → Neutral	$34 → $7
Dec-23-24	Initiated	H.C. Wainwright	Buy	$25
Nov-27-24	Initiated	Raymond James	Outperform	$23
Nov-18-24	Initiated	JMP Securities	Mkt Outperform	$18
Aug-28-24	Initiated	Oppenheimer	Outperform	$30
Apr-22-24	Initiated	Wells Fargo	Overweight	$30
Apr-15-24	Initiated	Guggenheim	Buy	$34
Mar-28-24	Initiated	UBS	Buy	$37
Mar-08-24	Initiated	Morgan Stanley	Overweight	$40
Feb-20-24	Initiated	Leerink Partners	Outperform	$31

Show Previous Ratings

Jun-25-25 08:00AM	FDA Grants RMAT Designation for enGenes Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer (Business Wire) +9.03%
Jun-17-25 08:00AM	enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jun-12-25 08:00AM	enGene Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Jun-04-25 08:30AM	enGene Announces the Resignation of its Chief Medical Officer (Business Wire) -8.81%
May-29-25 08:00AM	enGene to Present at the Jefferies Global Healthcare Conference (Business Wire)
07:30AM	Loading…
May-28-25 07:30AM	enGene Names Amy Pott as Chief Global Commercialization Officer (Business Wire)
Apr-29-25 07:30AM	enGene to Participate in Upcoming Investor Conferences (Business Wire)
Apr-28-25 08:00AM	enGene to Participate in Upcoming Investor Conferences (Business Wire)
Apr-23-25 10:13AM	Is enGene Holdings Inc. (ENGN) the Best Canadian Penny Stock to Invest in Now? (Insider Monkey)
Apr-04-25 08:00AM	enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Apr-01-25 08:00AM	enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum (Business Wire)
Mar-10-25 04:05PM	enGene Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Mar-04-25 08:00AM	enGene to Participate in the Leerink Partners Global Healthcare Conference (Business Wire)
Feb-04-25 08:00AM	enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-31-25 04:05PM	enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.63%
08:00AM	Loading…
Jan-30-25 08:00AM	enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC) (Business Wire)
Dec-30-24 04:05PM	enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) +5.14%
Dec-19-24 04:05PM	enGene Reports Full Year 2024 Financial Results and Provides a Business Update (Business Wire)
Nov-25-24 08:00AM	enGene to Participate in Upcoming Investor Conferences (Business Wire) +7.94%
Nov-05-24 08:00AM	enGene to Participate in Guggenheims Inaugural Healthcare Innovation Conference (Business Wire)
Oct-25-24 08:00AM	enGene Announces $60 Million Private Placement Financing (Business Wire)
Oct-22-24 04:05PM	enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -7.93%
Oct-21-24 08:45AM	enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer (Business Wire) +8.98%
Oct-01-24 04:05PM	enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Sep-26-24 06:30AM	Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort (Business Wire) -12.00%
Sep-14-24 10:08PM	enGene Holdings Inc. (ENGN): Wall Street Analysts Recommend This Canadian Stocks Right Now (Insider Monkey)
Sep-10-24 04:33PM	enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update (Business Wire)
Aug-28-24 04:05PM	enGene to Participate in Upcoming Investor Conferences (Business Wire)
Jul-24-24 04:05PM	enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
06:30AM	enGene Announces Appointment of Ron Cooper as Chief Executive Officer (Business Wire)
08:00AM	Loading…
Jul-18-24 08:00AM	NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors (GlobeNewswire)
Jun-14-24 07:01AM	enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update (Business Wire) -10.00%
May-29-24 07:30AM	enGene to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-15-24 04:05PM	enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors (Business Wire)
May-02-24 04:05PM	enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting (PR Newswire)
Apr-09-24 08:56AM	/C O R R E C T I O N -- enGene Inc./ (PR Newswire)
08:00AM	engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development (PR Newswire)
Mar-11-24 05:16PM	enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress (PR Newswire)
Mar-05-24 07:00AM	enGene To Present at the Leerink Partners Global Biopharma Conference (PR Newswire)
Feb-14-24 06:50AM	enGene Announces Oversubscribed $200 Million Private Placement Financing (PR Newswire) +116.54%
06:45AM	enGene Announces Leadership Succession Plan (PR Newswire)
Jan-30-24 07:00AM	enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary (PR Newswire) -7.11%
Jan-29-24 07:00AM	enGene Reports Full Year 2023 Financial Results and Recent Operational Progress (PR Newswire)
Dec-22-23 05:00PM	enGene Announces Expanded $50 Million Debt Facility with Hercules Capital (PR Newswire)
Dec-19-23 07:00AM	enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors (PR Newswire) +6.10%
Nov-29-23 07:00AM	enGene Appoints Ryan Daws as Chief Financial Officer (PR Newswire) -11.14%
Nov-13-23 09:55AM	Forbion co-leads 129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023 (GlobeNewswire) +5.36%
Nov-02-23 07:00AM	Lumira Ventures Portfolio Company enGene (Nasdaq:ENGN) Debuts as Publicly Traded Genetic Medicines Company (ACCESSWIRE) -5.00%
Nov-01-23 07:30AM	enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Medicines Company (PR Newswire) -7.81%

enGene Holdings, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The company was founded by Anthony T. Cheung on April 24, 2023 and is headquartered in Saint-Laurent, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Forbion Growth Opportunities F	10% Owner	Oct 30 '24	Buy	8.90	561,797	4,999,993	3,032,430	Nov 01 04:15 PM
Forbion Growth Opportunities F	10% Owner	Sep 30 '24	Buy	6.34	341,332	2,163,362	2,400,791	Oct 18 04:15 PM
Forbion Growth Opportunities F	10% Owner	Sep 27 '24	Buy	5.97	41,639	248,699	2,059,459	Oct 18 04:15 PM
Forbion Growth Opportunities F	10% Owner	Oct 01 '24	Buy	6.44	35,279	227,158	2,436,070	Oct 18 04:15 PM
Forbion Growth Opportunities F	10% Owner	Oct 07 '24	Buy	6.55	11,844	77,531	2,469,833	Oct 18 04:15 PM
Forbion Growth Opportunities F	10% Owner	Oct 02 '24	Buy	6.37	10,153	64,697	2,446,223	Oct 18 04:15 PM
Forbion Growth Opportunities F	10% Owner	Oct 04 '24	Buy	6.54	5,997	39,242	2,457,989	Oct 18 04:15 PM
Forbion Growth Opportunities F	10% Owner	Oct 03 '24	Buy	6.48	5,769	37,397	2,451,992	Oct 18 04:15 PM
Forbion Growth Opportunities F	10% Owner	Oct 08 '24	Buy	6.60	800	5,278	2,470,633	Oct 18 04:15 PM
Cooper Ronald Harold Wilfred	Chief Executive Officer	Sep 27 '24	Buy	5.70	10,000	57,000	10,000	Oct 01 08:02 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ENGN

enGene Holdings Inc

Upgrade your FINVIZ experience